Fifty Years

Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in single-cell analysis technology. Founded in 2015, the company has developed an AI-powered imaging and microfluidics platform that offers a non-invasive method for genetic testing with diagnostic-level accuracy. This platform enables researchers to classify and isolate viable cells based on their morphological characteristics, thus facilitating improved diagnosis and treatment of diseases. By providing detailed genetic health information through ordinary blood samples, Deepcell aims to enhance translational research, diagnostic testing, and therapeutic applications, ultimately reducing the need for invasive procedures in medical diagnostics.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.

Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

64x Bio develops a platform that accelerates and scales mammalian cell line discovery. It combines high-throughput screening with computational design loops to create optimized cell lines for viral vector production, focusing on those used in cell and gene therapies.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in single-cell analysis technology. Founded in 2015, the company has developed an AI-powered imaging and microfluidics platform that offers a non-invasive method for genetic testing with diagnostic-level accuracy. This platform enables researchers to classify and isolate viable cells based on their morphological characteristics, thus facilitating improved diagnosis and treatment of diseases. By providing detailed genetic health information through ordinary blood samples, Deepcell aims to enhance translational research, diagnostic testing, and therapeutic applications, ultimately reducing the need for invasive procedures in medical diagnostics.

64x Bio develops a platform that accelerates and scales mammalian cell line discovery. It combines high-throughput screening with computational design loops to create optimized cell lines for viral vector production, focusing on those used in cell and gene therapies.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

Gordian Biotechnology is a therapeutics company based in San Francisco, California, founded in 2018. It specializes in developing a unique screening platform aimed at enhancing the efficiency of gene therapy development for complex age-related diseases. The company's platform focuses on researching and creating therapeutic drugs that target premature aging in humans, with the goal of curing age-related conditions and improving skin health.

Tierra Biosciences, established in 2015 and based in San Francisco, specializes in developing cell-free technologies for molecule discovery. Its Next Generation Expression platform combines automation, computation, and high-throughput cell-free expression to express DNA from diverse microbial sources, enabling the production of molecules challenging to create using conventional laboratory methods. The company's protein platform integrates cell-free protein production with artificial intelligence, facilitating rapid, large-scale manufacturing akin to e-commerce simplicity. Formerly known as Synvitrobio, Inc., Tierra Biosciences changed its name in September 2018.

Lygos is a Berkeley, California based biotechnology company that engineers microbes to convert sugars into high-value industrial chemicals where biological production is cost-advantaged over petrochemicals. Throughput screening and strain construction enable rapid optimization of metabolic pathways to transform cheap, renewable feedstocks into scalable chemical products. The company pursues sustainable specialty chemicals designed to replace persistent and toxic substances with safer, cleaner, cost-effective alternatives. With a multidisciplinary, vertically integrated platform, Lygos collaborates with partners across the value chain to deliver high-performing, environmentally beneficial solutions for business customers. Founded in 2011, Lygos serves B2B clients by developing and delivering products that combine performance with environmental benefits.

Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in single-cell analysis technology. Founded in 2015, the company has developed an AI-powered imaging and microfluidics platform that offers a non-invasive method for genetic testing with diagnostic-level accuracy. This platform enables researchers to classify and isolate viable cells based on their morphological characteristics, thus facilitating improved diagnosis and treatment of diseases. By providing detailed genetic health information through ordinary blood samples, Deepcell aims to enhance translational research, diagnostic testing, and therapeutic applications, ultimately reducing the need for invasive procedures in medical diagnostics.

Cofactor Genomics is a biotechnology company that specializes in predictive immune modeling and RNA sequencing. By advancing precision medicine, Cofactor aims to address existing barriers in the healthcare sector, transitioning from single-analyte biomarkers to comprehensive multidimensional biomarkers through health expression models. The company operates one of the first CAP-certified clinical RNA sequencing laboratories, which enhances the efficiency and cost-effectiveness of clinical trials for their partners. Cofactor’s expertise encompasses molecular biology, informatics, and database management, allowing them to provide high-quality services tailored to the needs of the healthcare and pharmaceutical industries. Their focus on RNA biomarkers associated with responses to targeted therapeutics supports the commercialization of clinical diagnostic assays for oncologic, immunologic, and neurodegenerative diseases, ultimately contributing to medical research and improved patient outcomes.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

BillionToOne is a precision diagnostics company that develops a molecular testing platform for ultrasensitive, single-molecule DNA quantification. Its patented Quantitative Counting Templates (QCT) platform enables accurate, affordable molecular counting, supporting non-invasive prenatal screening through UNITY, which analyzes fetal cell-free DNA from a mother's blood to assess fetal genetic risks, including single-gene disorders. The company also applies its technology to oncology and monitoring cancer therapy response. Founded in 2016 and based in Menlo Park, California, BillionToOne aims to make prenatal testing safer and more accessible by replacing invasive procedures with simple blood tests, and to broaden molecular diagnostics for diverse patient populations.

Clear Genetics, Inc. is a digital health company based in San Francisco, California, that specializes in providing genetic counseling services to women, healthcare providers, and health systems. Established in 2016, the company offers Clearancy, a web application designed to deliver personalized genetic information for patients undergoing genetic testing and their healthcare practitioners. Clear Genetics collaborates with health systems, laboratories, and academic institutions to enhance patient access to genetic counseling and testing across various medical specialties, including prenatal care, cardiology, carrier screening, hereditary cancer, and pediatrics. As of November 2019, Clear Genetics operates as a subsidiary of Invitae Corporation.

Lygos is a Berkeley, California based biotechnology company that engineers microbes to convert sugars into high-value industrial chemicals where biological production is cost-advantaged over petrochemicals. Throughput screening and strain construction enable rapid optimization of metabolic pathways to transform cheap, renewable feedstocks into scalable chemical products. The company pursues sustainable specialty chemicals designed to replace persistent and toxic substances with safer, cleaner, cost-effective alternatives. With a multidisciplinary, vertically integrated platform, Lygos collaborates with partners across the value chain to deliver high-performing, environmentally beneficial solutions for business customers. Founded in 2011, Lygos serves B2B clients by developing and delivering products that combine performance with environmental benefits.

Lygos is a Berkeley, California based biotechnology company that engineers microbes to convert sugars into high-value industrial chemicals where biological production is cost-advantaged over petrochemicals. Throughput screening and strain construction enable rapid optimization of metabolic pathways to transform cheap, renewable feedstocks into scalable chemical products. The company pursues sustainable specialty chemicals designed to replace persistent and toxic substances with safer, cleaner, cost-effective alternatives. With a multidisciplinary, vertically integrated platform, Lygos collaborates with partners across the value chain to deliver high-performing, environmentally beneficial solutions for business customers. Founded in 2011, Lygos serves B2B clients by developing and delivering products that combine performance with environmental benefits.

Cofactor Genomics is a biotechnology company that specializes in predictive immune modeling and RNA sequencing. By advancing precision medicine, Cofactor aims to address existing barriers in the healthcare sector, transitioning from single-analyte biomarkers to comprehensive multidimensional biomarkers through health expression models. The company operates one of the first CAP-certified clinical RNA sequencing laboratories, which enhances the efficiency and cost-effectiveness of clinical trials for their partners. Cofactor’s expertise encompasses molecular biology, informatics, and database management, allowing them to provide high-quality services tailored to the needs of the healthcare and pharmaceutical industries. Their focus on RNA biomarkers associated with responses to targeted therapeutics supports the commercialization of clinical diagnostic assays for oncologic, immunologic, and neurodegenerative diseases, ultimately contributing to medical research and improved patient outcomes.